{"entity":{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","aka":[],"tldr":"Making the pure form of lutetium-177 used in cancer drugs like Pluvicto requires starting from a rare, heavily purified metal called ytterbium-176. Almost all of the world's supply of that starting material has come from one country, which is a risky place for the whole medicine to depend on.","summary":"No-carrier-added lutetium-177 (177Lu), the form used in Pluvicto and Lutathera, is made by neutron-irradiating a target of ytterbium enriched to above 96-99% in the stable isotope ytterbium-176, then chemically separating the trace lutetium-177 produced. Only about one in 5,000 atoms in the irradiated target ends up as lutetium-177, and producing the same activity by this route needs roughly a thousand times more enriched starting material than the alternative (but lower-purity) carrier-added route using enriched lutetium-176. There is no accelerator-based alternative: no-carrier-added Lu-177 can only be made by neutron irradiation of Yb-176.\n\nThe enrichment step itself -- separating Yb-176 from the other six stable ytterbium isotopes -- has historically been dominated by Russian electromagnetic separators (calutrons), described by the EU's Economic and Social Committee as 100% European dependence on Russia for this specific material. The US Department of Energy's Oak Ridge National Laboratory restarted its own electromagnetic separation in the early 2020s but as of 2022 could only offer 'research quantities' not available for commercial resale, and Western capacity has generally atrophied because the customer base for any single enriched isotope is small and capital costs are high.\n\nThe same underlying problem -- a handful of highly specialised, low-throughput separation facilities feeding a fast-growing radioligand therapy market -- applies to other enriched targets in the pipeline (enriched molybdenum-100 for cyclotron-based Mo-99/Tc-99m, enriched gadolinium for astatine-211 routes), making enriched stable-isotope supply a structural constraint on the whole field, not just on lutetium-177.","asOf":"2026-09-22","links":[{"label":"Challenges and future options for the production of lutetium-177 (EJNMMI, 2021)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8241800/"},{"label":"One country's isotope, everyone's cancer drug (Problem Genome brief on Yb-176 dependence)","url":"https://www.problemgenome.com/briefs/health-yb176-enriched-isotope-single-country-supply"},{"label":"DOE Isotope R&D and Production, FY2025 budget request (stable isotope enrichment priorities)","url":"https://www.energy.gov/sites/default/files/2024-03/FY2025-PresidentsRequest-IRP.pdf"}],"tags":["supply chain","ytterbium-176","lutetium-177","enrichment"],"related":["idea-reg-yb176-enrichment-capacity","b-mo99-supply","b-ac225-supply","tc-99m","mo-99","lu-177","at-211"],"indications":[],"sections":[],"technologies":["therapy-isotope-supply-chain","research-reactor-isotope-production","lu177-radioligand-therapy"],"targets":[],"drugs":["pluvicto","lutathera","itm-11"],"companies":["novartis","itm","ntp-radioisotopes","curium"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"stage":"regulation-manufacturing","severity":"major","metrics":[{"label":"Fraction of irradiated ytterbium-176 target atoms converted to lutetium-177","value":"~1 in 5,000","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8241800/"},{"label":"Extra enriched target material needed for the no-carrier-added (Yb-176) route vs the carrier-added (Lu-176) route, for equivalent activity","value":"~1,000-fold more","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8241800/"},{"label":"EU dependence on Russia for enriched ytterbium-176 supply","value":"100% (EU Economic and Social Committee statement)","url":"https://www.problemgenome.com/briefs/health-yb176-enriched-isotope-single-country-supply"}],"causes":["There is no feasible accelerator- or proton-based production route for lutetium-177: only neutron irradiation works, which locks the process to a small number of high-flux research reactors and to whichever enriched target is available to them.","Enrichment of ytterbium-176 requires electromagnetic separators (calutrons), gas centrifuges, or laser separation -- all capital-intensive, low-throughput technologies with very few operators worldwide.","The customer base for any single enriched stable isotope is small, so for decades it was cheaper to buy Russian material than to build competing Western capacity, and that Western capacity atrophied.","Chemical recovery and recycling of the expensive enriched ytterbium target after irradiation is technically demanding, so yields and reuse rates limit how far existing enriched stock can be stretched."],"currentEfforts":["US DOE Isotope Program restarting electromagnetic isotope separation and building the Stable Isotope Production Facility at Oak Ridge National Laboratory, initially for other isotopes (e.g. xenon-129) with stable-isotope enrichment as a stated strategic priority including ytterbium-176.","EU SAMIRA action plan and Euratom research calls specifically funding alternative, non-Russian ytterbium-176 production routes.","Radiopharmaceutical manufacturers (Novartis, ITM, others) reported to be pursuing multiple, geographically diversified Yb-176 supply agreements to reduce single-country exposure."],"successLooksLike":"At least two commercially viable, non-Russian sources of pharmaceutical-grade enriched ytterbium-176 (or an alternative no-carrier-added Lu-177 production route), so that lutetium-177 supply is not exposed to a single country's export policy."},"route":"/bottlenecks/b-enriched-target-material/","neighbours":{"idea":[{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/"}],"bottleneck":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/"}],"isotope":[{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"},{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/"},{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"drug":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"company":[{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/"},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/"}]}}